Senseonics Holdings, Inc. Announces Retirement of Chief Financial Officer
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced the retirement of Chief Financial Officer, R.
Don Elsey. Mr. Elsey has agreed to remain in his current role and to
step down when a replacement is appointed. He will then continue with
the company in an advisory role to ensure an orderly transition and
completion of the company’s annual SEC filings for the 2018 fiscal year.
“Don has been an important part of the growth of Senseonics as our CFO,
and we thank him for his service and high level of professionalism
throughout his tenure at Senseonics,” said Tim Goodnow, President and
Chief Executive Officer. “Over the past several years, we have
successfully completed an IPO and subsequent capital raises, enabling us
to execute product launches in Europe, continue our pipeline development
initiatives and position the company for a successful commercial launch
that is underway in the U.S. Don has contributed much to all of these
efforts, and we wish him well in his next pursuits.”
“It has been a pleasure working with the dedicated and talented team at
Senseonics,” stated Don Elsey, Chief Financial Officer. “I am proud of
what we have accomplished and am confident the company is on a solid
path toward delivering life changing technology to people with diabetes.”
ABOUT SENSEONICS
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformative glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. From its inception, Senseonics has been
advancing the integration of novel, fluorescence sensor technology with
smart wearable devices. The Eversense® CGM System received PMA approval
from the FDA for up to 90 days of continuous use and is available in the
United States. The Eversense® CGM XL System received CE mark for up to
180 days of continuous use and is available in Europe. For more
information on Senseonics, please visit www.senseonics.com.
FORWARD LOOKING STATEMENTS
Any statements in this press release about future expectations, plans
and prospects for Senseonics, including statements about the expanded
commercialization of Eversense in Europe, the launch in the U.S., and
delivering life changing technology to people with diabetes, and other
statements containing the words “expect,” “intend,” “may,” “projects,”
“will,” and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: uncertainties in the development and regulatory approval
processes, uncertainties inherent in the commercial launch and
commercial expansion of the product, and such other factors as are set
forth in the risk factors detailed in Senseonics’ Annual Report on Form
10-K for the year ended December 31, 2017, Senseonics’ Quarterly Report
on Form 10-Q for the quarter ended September 30, 2018, and Senseonics’
other filings with the SEC under the heading “Risk Factors.” In
addition, the forward-looking statements included in this press release
represent Senseonics’ views as of the date hereof. Senseonics
anticipates that subsequent events and developments will cause
Senseonics’ views to change. However, while Senseonics may elect to
update these forward-looking statements at some point in the future,
Senseonics specifically disclaims any obligation to do so except as
required by law. These forward-looking statements should not be relied
upon as representing Senseonics’ views as of any date subsequent to the
date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005912/en/
INVESTOR CONTACT
Lynn Lewis or Philip Taylor
Investor
Relations
415-937-5406
[email protected]
Source: Senseonics Holdings, Inc.